Compounding Semaglutide: What 503A Pharmacies Can Legally

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Compounded semaglutide sits in a regulatory category that has evolved rapidly between 2022 and 2026. This article covers the FDA shortage-list context that opened the compounding pathway, the 2024 shortage resolution that narrowed it, the difference between legitimate 503A compounding pharmacies and unregulated sources, and how PlexusDx operates inside the legitimate pathway.

The FDA shortage-list context (2022–2024)

When the FDA listed semaglutide on its drug shortage list in 2022, federal law (Section 503A of the FD&C Act) opened a pathway for state-licensed compounding pharmacies to compound semaglutide formulations to meet patient demand. Compounded preparations are not FDA-approved branded products — they are pharmacy-prepared medications dispensed under an individual prescription. The shortage-list pathway became the primary mechanism for broader patient access during the supply gap.

The 2024 FDA shortage resolution

In 2024, the FDA declared the semaglutide shortage resolved. This narrowed the legal pathway for compounding semaglutide. Legitimate 503A compounding remains permitted in specific clinical contexts — including when an individual patient has a documented clinical need that the FDA-approved product cannot meet (e.g., specific dosage requirements, allergic reactions to inactive ingredients, or the need for an alternative formulation). The regulatory environment continues to evolve.

Legitimate compounding vs unregulated sources

Legitimate compounded semaglutide: prepared by a state-licensed 503A compounding pharmacy under an individual prescription from a licensed clinician, with documented sterility and quality controls. Unregulated sources: foreign websites, "research chemical" suppliers, and platforms without documented prescriber-pharmacy infrastructure. The FDA has issued multiple warnings about counterfeit GLP-1 products sold through unregulated channels.

How PlexusDx operates

PlexusDx offers clinician-supervised compounded semaglutide protocols inside its Weight Management Protocols — sourced through a licensed compounding pharmacy and prescribed only after a documented clinical evaluation. The protocol options include Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, Tirzepatide Oral, Microdose GLP-1, and GLP-Squared.

PlexusDx offers semaglutide through its Weight Management Protocols, including Semaglutide protocol. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in GLP1R, FTO, MC4R, and TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Disclaimer: This article is educational. PlexusDx offers semaglutide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use it. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Learn more about the PlexusDx Semaglutide protocol or the oral semaglutide protocol inside the Weight Management Protocols collection. To start upstream with the genetic context, take the Precision Peptide Genetic Test first.

Frequently Asked Questions

Is compounded semaglutide legal?

Compounding semaglutide through a state-licensed 503A compounding pharmacy under an individual prescription from a licensed clinician is legal when the regulatory criteria are met. The FDA-approved branded product is the regulatory baseline; compounded preparations operate under separate provisions that have evolved since the 2024 shortage resolution.

Is compounded semaglutide the same as branded?

No — they are different regulatory categories. Branded products are FDA-approved manufactured medications with a specific NDA. Compounded preparations are pharmacy-prepared medications dispensed under an individual prescription. Quality, sterility, and consistency depend on the specific compounding pharmacy and oversight.

How much cheaper is compounded semaglutide?

Compounded semaglutide has historically priced significantly below branded list price, though specific pricing varies by pharmacy, protocol, and prescriber relationship. Cost is one consideration; regulatory compliance, prescriber oversight, and pharmacy quality are equally important.

Does genetic testing predict response to compounded GLP-1?

No. The Precision Peptide Genetic Test does not predict response to compounded or branded GLP-1 protocols. It analyzes pathway-level variants in GLP1R, FTO, and MC4R and other genes that shape baseline GLP-1 biology — the upstream context for any GLP-1 conversation with a healthcare provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Compounding Semaglutide: What 503A Pharmacies Can Legally Do

Compounded semaglutide explained: the FDA shortage-list context, the 2024 resolution, legitimate 503A compounding vs unregulated sources, and how PlexusDx operates inside the legitimate pathway.